Paradigm Biopharmaceuticals (ASX:PAR) has activated a clinical site in Australia, with the first patient providing consent to participate in the phase three trial testing injectable pentosan polysulfate sodium (iPPS) for knee osteoarthritis pain, according to a Tuesday filing with the Australian bourse.

The trial also includes 48 US sites preparing for activation, with first patient consent and dosing expected next quarter, the filing said.